Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Ann N Y Acad Sci. 2009 Sep;1174:88–98. doi: 10.1111/j.1749-6632.2009.05000.x

Figure 4. Loading DCs with tumor antigens.

Figure 4

In our initial trials, DCs were loaded with short synthetic peptides, the major limitations of which are MHC restriction and the lack of cognate CD4+ T cell epitopes. Next step was to test loading DCs with killed tumor cells. These are able to generate a broad repertoire of CD4+ and CD8+ T cells. Long synthetic peptides might overcome MHC restriction and allow us to better control T cell repertoire. These studies will lay the ground for selection of long peptides that can be fused with anti-DC antibodies for ex vivo and in vivo DC targeting.